Table 2. The reported prevalence of cardiac amyloidosis with different presentations.

Conditions	Any CA	ATTRwt	ATTRv
HFpEF	13-17%	17% ATTR deposits (autopsy); 5% moderate to severe deposits; > 80 y 40%, male predominant; < 65 y 0%	Varying levels of cardiac involvement by different TTR variants
HF	11.4% in Afro-Caribbean patients, UK		8.5% (V122I) in Afro-Caribbean patients, UK
Severe AS for surgical valve replacement	6-12%
TAVR	8-16%
Degenerative AS	16%
Low-flow, low-gradient pattern AS	30%
HCM			5%, France

AS, aortic stenosis; ATTRv, hereditary transthyretin amyloid cardiomyopathy; ATTRwt, wild type transthyretin amyloid cardiomyopathy; CA, cardiac amyloidosis; HCM, hypertrophic cardiomyopathy; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; TAVR, transcatheter aortic valve replacement; TTR, transthyretin; UK, United Kingdom; y, year.